Azenta Inc
XMUN:BA3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
A
|
Azenta Inc
XMUN:BA3
|
US |
|
S
|
Smothong Group PCL
SET:SMO
|
TH |
Azenta Inc
Azenta Inc. sells tools and services that help life science customers store, track, move, and analyze biological samples. Its core products include automated sample storage systems, lab automation equipment, cryogenic storage, and the software and consumables needed to manage those samples safely. It also offers genomic and sequencing services for research and clinical work. Its main customers are pharmaceutical and biotech companies, hospitals, academic research labs, and other organizations that handle valuable samples such as blood, tissue, and DNA. Azenta makes money by selling equipment, consumables, service contracts, storage and logistics services, and testing or sequencing services. That mix gives it both one-time product sales and recurring service revenue. What makes Azenta different is that it sits in the infrastructure layer of life sciences. Instead of making drugs or running experiments itself, it helps customers protect sample quality, keep large collections organized, and get material to the right place at the right time. That makes it a behind-the-scenes partner for labs that depend on reliable sample handling and data traceability.
Azenta Inc. sells tools and services that help life science customers store, track, move, and analyze biological samples. Its core products include automated sample storage systems, lab automation equipment, cryogenic storage, and the software and consumables needed to manage those samples safely. It also offers genomic and sequencing services for research and clinical work.
Its main customers are pharmaceutical and biotech companies, hospitals, academic research labs, and other organizations that handle valuable samples such as blood, tissue, and DNA. Azenta makes money by selling equipment, consumables, service contracts, storage and logistics services, and testing or sequencing services. That mix gives it both one-time product sales and recurring service revenue.
What makes Azenta different is that it sits in the infrastructure layer of life sciences. Instead of making drugs or running experiments itself, it helps customers protect sample quality, keep large collections organized, and get material to the right place at the right time. That makes it a behind-the-scenes partner for labs that depend on reliable sample handling and data traceability.
Beat: Azenta said third-quarter revenue of $161 million came in ahead of expectations, with organic growth of 9% and adjusted EBITDA margins of 11.4%, up 610 basis points sequentially.
Demand: Sample Management Solutions and Multiomics both grew organically, helped by recurring revenue businesses, stronger activity in Europe and China, and a modest pickup in North America.
Outlook: Full-year revenue guidance was raised to $613 million to $618 million and organic revenue guidance improved to approximately flat to up 1%, but management stayed cautious about the fourth quarter and the broader market.
Multiomics: North America improved modestly, but management said the recovery is still early and uneven; Europe and China remained strong, while Sanger continued to weigh on results.
Capital allocation: Azenta completed the B Medical Systems divestiture, repurchased $50 million of stock, and said it still has about $200 million left under its buyback program.
Turnaround: Management emphasized ongoing footprint rationalization, modular store redesign, and cost optimization in automated stores, cryo systems, and Multiomics as key parts of the turnaround.